| Ytd | 8.13% | |
| 1y | -46.25% |
| Open | 19.39 | Prev Close | 19.15 | Low | 19.01 | High | 19.44 | Mkt Cap | 2.15B |
| Vol | 105.04K | Avg Vol | 893.39K | EPS | -1.70 | P/E | N/A | Forward P/E | -10.97 |
| Beta | 0.78 | Short Ratio | 7.54 | Inst. Own | 31.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 19.19 | 200-d Avg | 21.32 | 1yr Est | 33.30 |
ZLAB News
- European Medicines Agency's Committee for Orphan Medicinal Products recognized zoci's prel
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Mon
Zai Lab reported promising preliminary data from an ongoing registration-enabling multicenter, Phase
Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and lowers the pri
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which beat the analyst consensu
Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed i
Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688))) today announced a clinical collaboratio
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced a global clinical trial collaboration wi
JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the pr
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-dev
Cantor Fitzgerald analyst Li Watsek maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.46) per share which missed the analyst consen
JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the pr
- Zocilurtatug pelitecan (Zoci) positioned to become Zai Lab's first global oncology launch, wit
UBS analyst Michael Yee initiates coverage on Zai Lab (NASDAQ:ZLAB) with a Buy rating and announc
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that China's National Medical Produc
Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug br
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Product
Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced the dosing of the first participant in a
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced updated data from the global Phase 1 clin
- Oral presentation to feature new data highlighting the potential of zocilurtatug pelitecan (former
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival be
Citigroup analyst Yigal Nochomovitz maintains Zai Lab (NASDAQ:ZLAB) with a Buy and raises the pri
Zai Lab (NASDAQ:ZLAB) affirms FY2025 sales outlook from $560.000 million-$590.000 million to $560.00
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.37) per share which beat the analyst consensu
Leerink Partners analyst Jonathan Chang maintains Zai Lab (NASDAQ:ZLAB) with a Outperform and rai
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly los
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company p
U.S. stocks traded mostly mixed, with the Dow Jones index gaining more than 100 points on Monday. H